# US 2025/0375428 A1 · Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375428 A1
- Document ID: US20250375428A1
- Status: Published application
- Kind: A1
- Application number: 19/016,686
- Filed: 2025-01-10
- Published: 2025-12-11
- Earliest claimed: 2022-07-12
- Assignees: Hotspot Therapeutics, Inc.
- Applicants: Hotspot Therapeutics, Inc.
- Inventors: Fang WANG; Yilin QI; Timothy P. REILLY
- Web page: https://patentgrep.com/patent/US20250375428A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/409: having four such rings, e.g. porphine derivatives, bilirubin, biliverdine (hemin, hematin A61K31/555)
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/549: having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to treatment of a subject in need thereof of comprising administering a therapeutically effective amount of a CBL-B inhibitor and a therapeutically effective amount of an anti PD-1/anti-PD-L1 agent.

## Claims

### Claim 1

A method of treating a disease or condition associated with cell proliferation comprising administering to a subject in need thereof a therapeutically effective amount of a CBL-B inhibitor and therapeutically effective amount of an anti-PD1/anti-PD-L1 agent.

### Claim 2

A method of treating a disease or condition associated with cell proliferation comprising administering to a subject in need thereof a therapeutically effective amount of a CBL-B inhibitor wherein the subject has previously been treated with an anti-PD1/anti-PD-L1 agent.

### Claim 3

A method of treating a disease or condition associated with cell proliferation comprising administering to a subject in need thereof a therapeutically effective amount of an anti-PD1/anti-PD-L1 agent wherein the subject has previously been treated with a CBL-B inhibitor.

### Claim 4 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein the CBL-B inhibitor is a compound of formula (A):
or pharmaceutically acceptable salts thereof,
wherein
Y is selected from the group ═C(H)—, ═C(Ra)— or ═N—;
Z is ═O or ═S;
E is optionally substituted 5-6 membered heterocyclyl;
B is optionally substituted phenyl, optionally substituted 8-10 membered bicyclyl, or optionally substituted 5-6 membered heteroaryl;
C is optionally substituted 5-6 membered heterocyclyl;
X is an optionally substituted C1-C3 alkylene chain, wherein one or more methylene units is optionally replaced by —N(H)—, —N(R1)—, —O—, —S—, —SO—, —SO2—, optionally substituted 3-6-membered carbocyclyl, and optionally substituted 3-6-membered heterocylyl, wherein X is optionally substituted with an optionally substituted group selected from a group consisting of halogen, C1-C3 aliphatic, phenyl, 3-6-membered heteroaryl, 3-6-membered heterocylyl, and —(CH2)(3-6-membered carbocyclyl);
each Ra is independently selected from the group consisting of L-A, halogen, —CN, —OH, —OR1, —NH2, —NR1R2, —SH, —SR1, —SFs, —CO2H, —CO2R1, —C(O)R1, —CONH2, —CONR1R2, —SO2NH2, —SO2NR1R2, —SO2OH, —SO2OR1, —S(O)R1, —S(O)2R1, —S(O)(NH)R1, —S(O)(NR1)R1, optionally substituted C1-C6 aliphatic, optionally substituted C1-C6 heteroalkyl, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted phenyl, and optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S, wherein Ra is optionally substituted with 1-5 instances of Ra1;
L is an optionally substituted C1-C3 alkylene chain;
A is selected from the group consisting of optionally substituted C3-C7 carbocylyl, optionally substituted C1-C6 heteroalkyl, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted phenyl, and optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S, wherein A is optionally substituted with 1-5 instances of Ra1;
each Ra1 is independently selected from the group consisting of halogen, —CN, —OH, —OR1, —NH2, —NR1R2, —SH, —SR1, —SFs, —CO2H, —CO2R1, —CONH2, —CONR1R2, —SO2NH2, —SO2NR1R2, —SO2OH, —SO2OR1, —S(O)R1, —S(O)2R1, —S(O)(NH)R1, —S(O)(NR1)R1, optionally substituted C1-C6 aliphatic, optionally substituted C1-C6 heteroalkyl, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted phenyl, and optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S;
each Rb is independently selected from the group consisting of, halogen, —CN, —OH, —OR1, —NH2, —NR1R2, —SH, —SR1, —SFs, —CO2H, —CO2R1, —CONH2, —CONR1R2, —SO2NH2, —SO2NR1R2, —SO2OH, —SO2OR1, —S(O)R1, —S(O)2R1, —S(O)(NH)R1, —S(O)(NR1)R1, optionally substituted C1-C6 aliphatic, optionally substituted C1-C6 heteroalkyl, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted phenyl, and optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S;
each Rc is independently selected from the group consisting of hydrogen, optionally substituted C1-C6 aliphatic, OR1, —NH2, —NR1R2, optionally substituted phenyl, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S, —C(O)R3, —CO2R3, —C(O)NHR3, and —SO2R3;
each R1 is independently selected from the group consisting of optionally substituted C1-C6 aliphatic, optionally substituted phenyl, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S, —C(O)R3, —CO2R3, —C(O)NHR3, and —SO2R3;
each R2 is independently selected from the group consisting of hydrogen, optionally substituted C1-C6 aliphatic, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted phenyl, and optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S;
or R1 and R2 are taken together with their intervening atom(s) to form a 3-8-membered heterocyclyl ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S, or an optionally substituted 5-6-membered heteroaryl ring containing 1-4 heteroatoms selected from the group consisting of N, O, and S.
each R3 is independently selected from the group consisting of optionally substituted C1-C6 aliphatic, optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S, optionally substituted phenyl, optionally substituted 5-6-membered heteroaryl containing 1-4 heteroatoms each selected from the group consisting of N, O and S;
n is 0, 1, 2, 3, 4, or 5;
m is 0, 1, 2, 3, or 4; and
p is 0, 1, 2, 3, or 4.

### Claim 5

The method of any of the previous claims, wherein C is selected from the group consisting of optionally substituted triazolyl, optionally substituted pyrazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted thiadizolyl, optionally substituted pyridinyl, optionally substituted pyrazinyl, optionally substituted pyrimidinyl, and optionally substituted pyridazinyl.

### Claim 6

The method of any of the previous claims, wherein the compound is of Formula (B):
or pharmaceutically acceptable salts thereof.

### Claim 7

The method of any of the previous claims, wherein the compound is of Formula (I):
or pharmaceutically acceptable salts thereof.

### Claim 8

The method of any of the previous claims, wherein the compound is of Formula (Ia) or (IIa):
or a pharmaceutically acceptable salt thereof,
wherein each W is independently selected from N or C.

### Claim 9

The method of any of the previous claims, wherein the compound is of formula (Ia1) or (IIa1):
or a pharmaceutically acceptable salt thereof.

### Claim 10

The method of any of the previous claims, wherein the compound is of Formula (Ia2), (Ia3), or (Ia4):
or a pharmaceutically acceptable salt thereof.

### Claim 11

The method of any of the previous claims, wherein the compound is of formula (Ib) or (IIb):
or pharmaceutically acceptable salts thereof,
wherein each W is independently selected from N or C.

### Claim 12

The method of any of the previous claims, wherein the compound is of formula (Ic) or (IIc):
or pharmaceutically acceptable salts thereof.

### Claim 13

The method of any of the previous claims, wherein R∘ is optionally substituted C1-C3 aliphatic.

### Claim 14

The method of any of the previous claims, wherein each R∘ is independently selected from the group consisting of methyl, —CD3, —CHF2

### Claim 15

The method of any of the previous claims, wherein Rc is methyl.

### Claim 16

The method of any of the previous claims, wherein X is optionally substituted C1-C2 alkylene.

### Claim 17

The method of any of the previous claims, wherein X is
or optionally substituted C2 alkylene, wherein one methylene unit is replaced with

### Claim 18

The method of any of the previous claims, wherein X is selected from the group consisting of

### Claim 19

The method of any of the previous claims, wherein Ra is L-A.

### Claim 20

The method of any of the previous claims, wherein L is —CH2— or —CH(CH3)—.

### Claim 21

The method of any of the previous claims, wherein A is optionally substituted 3-6 membered heterocyclyl containing 1-4 heteroatoms each selected from the group consisting of N, O, and S.

### Claim 22

The method of any of the previous claims, wherein Ra is selected from halogen, —CN, —C(O)R1, —CO2H, —CONR1R2, optionally substituted C1-C6 aliphatic, and optionally substituted C1-C6 heteroalkyl.

### Claim 23

The method of any of the previous claims, wherein each Ra is independently selected from the group consisting of halogen, —CN, —CO2H, —CHO, —CHF2, —CF3, —OMe, —S(O)2NHMe,

### Claim 24

The method of any of the previous claims, wherein the compound is selected from the group consisting of
Cmpd
No.
Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278_p1
278_p2
279
280
281
282
283
284
285
286
287_P1
287_P2
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
329
321
322
323
324
325
326
327
328
329
330
331
332_p1
332-p2
333
334
335
336
337
338
339_P1
339_P2
340_P1
340_P2
341
342
343
344
345
346
347
348
349
350
351_P1
351_P2
352_P1
352_P2
353
354
355
356
357
358
359
360
361
362_P1
362_P2
363_P1
363_P2
364_P1
364_P2
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380_P1
380_P2
381_P1
381_P2
382_P1
382_P2
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401_P1
401_P2
402
403_P1
403_P2
404
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434_P1
434_P2
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470_P1
470_P2
471
472_P1
472_P2
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506_P1
506_P2
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550_P1
550_P2
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565_P1
565_P2
566
567
568
569
570
571
572
573_P1
573_P2
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597_P1
597_P2
598
599
600
601
602
603
604
605
606
607
608
609
610_P1
610_P2
611
612_P1
612_P2
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627_P1
627_P2
628_P1
628_P2
or a pharmaceutically acceptable salt thereof.

### Claim 25

The method of any of the previous claims, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 26

The method of any of the previous claims, wherein the compound is
or a pharmaceutically acceptable salt thereof.

### Claim 27

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of 60-600 mg.

### Claim 28

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of 60-600 mg.

### Claim 29

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of 60-100 mg.

### Claim 30

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of 100-200 mg.

### Claim 31

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of 200-300 mg.

### Claim 32

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of 300-400 mg.

### Claim 33

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of 400-500 mg.

### Claim 34

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of 500-600 mg.

### Claim 35

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of about 60 mg.

### Claim 36

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of about 100 mg.

### Claim 37

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of about 150 mg.

### Claim 38

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of about 200 mg.

### Claim 39

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of about 250 mg.

### Claim 40

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of about 300 mg.

### Claim 41

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of about 350 mg.

### Claim 42

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of about 400 mg.

### Claim 43

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of about 450 mg.

### Claim 44

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of about 500 mg.

### Claim 45

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of about 550 mg.

### Claim 46

The method of any of the previous claims, wherein the CBL-B inhibitor is administered at a dose of about 600 mg.

### Claim 47

The method of any of the previous claims, wherein the anti-PD1/anti PD-L1 agent is an anti-PD1 antibody.

### Claim 48

The method of any of the previous claims, wherein the anti-PD1/anti PD-L1 agent is selected from the group consisting of B0146, nivolumab, pembrolizumab, atezolizumab, dostarlimab, cemiplimab, durvalumab, and avelumab.

### Claim 49 (depends on 48)

The method claim 48, wherein the anti-PD1/anti PD-L1 agent is B0146.

### Claim 50 (depends on 49)

The method of claim 49, wherein B0146 is administered at a dose of 10 mg/kg.

### Claim 51 (depends on 50)

The method of claim 50, wherein B0146 is administered at a dose of 10 mg/kg biweekly.

### Claim 52 (depends on 50)

The method of claim 50, wherein B0146 is administered at a dose of 10 mg/kg biweekly for 3 weeks.

### Claim 53

The method of any of the previous claims, wherein the disease or condition associated with cell proliferation is hyperplasia or cancer.

### Claim 54 (depends on 53)

The method of claim 53, wherein cancer is a hematologic cancer.

### Claim 55 (depends on 54)

The method of claim 54, wherein the hematologic cancer is selected from a group consisting of lymphoma, leukemia, and myeloma.

### Claim 56 (depends on 55)

The method of claim 55, wherein cancer is a non-hematologic cancer.

### Claim 57 (depends on 56)

The method of claim 56, wherein the non-hematologic cancer is a sarcoma or a carcinoma.

### Claim 58 (depends on 53)

The method of claim 53, wherein cancer is liver cancer.

### Claim 59 (depends on 53)

The method of claim 53, wherein cancer is colorectal cancer.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 1-57, wherein the subject has one or more of increased T-cell activation, increased T-cell proliferation, decreased T-cell exhaustion, decreased T-cell anergy and decreased T-cell tolerance after administration of compound of any of claims 1-15 or a pharmaceutical composition of claim 16.

### Claim 61 (depends on 60)

The method of claim 60, wherein increased T-cell activation comprises increased production of a cytokines.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of claims 1-57, wherein the subject has increased NK-cell activation.

### Claim 63

The method of 62, the increased NK-cell activation comprises increased production of cytokines.
